Skip to main content

Table 5 CSF P-tau, VILIP-1, and YKL-40 across clinical diagnoses and Aβ pathology

From: Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease

Different groups P-tau VILIP-1 YKL-40 Difference P-tau vs VILIP-1 Difference P-tau vs YKL-40 Difference VILIP-1 vs YKL-40
Associations between neurodegeneration biomarkers and Aβ pathology within diagnostic group
 CN Aβ vs CN Aβ+ 0.500 (0.033) 0.372 (0.168) 0.582 (0.144) 0.128 (0.713) −0.083 (0.855) −0.211 (0.657)
 sMCI Aβ vs sMCI Aβ+ 0.854 (0.014) − 0.014 (0.970) 0.210 (0.634) 0.869 (0.092) 0.645 (0.246) −0.224 (0.699)
 pMCI Aβ vs pMCI Aβ+ 1.130 (0.002) 0.619 (0.017) 0.466(0.291) 0.516 (0.371) 0.669 (0.243) 0.153 (0.809)
Associations between neurodegeneration biomarkers and combinations of clinical diagnosis and Aβ pathology
 CN Aβ vs CN Aβ+ 0.500 (0.033) 0.372 (0.168) 0.582(0.144) 0.128 (0.713) −0.083 (0.855) −0.211 (0.657)
 CN Aβ vs sMCI Aβ+ 0.716 (0.003) 0.274 (0.236) 0.055 (0.875) 0.442 (0.181) 0.661 (0.124) 0.219(0.603)
 CN Aβ vs pMCI Aβ+ 1.120 (< 0.001) 0.941 (< 0.001) 0.344 (0.191) 0.176 (0.590) 0.773 (0.032) 0.597 (0.107)
 CN Aβ vs AD Aβ+ 1.100 (< 0.001) 0.789 (0.007) 0.668 (0.038) 0.313 (0.378) 0.435 (0.262) 0.121 (0.773)
 CN Aβ vs sMCI Aβ −0.234 (0.261) 0.244 (0.439) −0.198 (0.595) − 0.477 (0.214) −0.036 (0.934) 0.441 (0.370)
 CN Aβ vs pMCI Aβ −0.130 (0.560) − 0.018 (0.959) −0.264 (0.583) − 0.112 (0.785) 0.134 (0.800) 0.246 (0.678)
  1. In different combinations of clinical diagnosis and Aβ pathology, data are are estimates from linear mixed-effects models evaluating effects of Aβ within diagnostic groups (top 3 rows), and differences between Aβ CN and other combinations of diagnosis and Aβ pathology (bottom 6 rows). Results are β-coefficient (P-value). Bold values indicate significant associations
  2. Abbreviations: VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1, CN cognitively normal, sMCI stable mild cognitive impairment, pMCI progressive mild cognitive impairment, AD Alzheimer’s disease